Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8984-8998

  Scott, James S ^a   Bowker, Suzanne S ^a   Brocklehurst, Katy J ^a   Brown, Hayley S ^a   Clarke, David S ^a   Easter, Alison ^a,c   Ertan, Anne ^b   Goldberg, Kristin ^a   Hudson, Julian A ^a   Kavanagh, Stefan ^a   Laber, David ^a   Leach, Andrew G ^a   Macfaul, Philip A ^a   Martin, Elizabeth A ^a   McKerrecher, Darren ^a   Schofield, Paul ^a,d,e   Svensson, Per H ^b   Teague, Joanne ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d SP TECHNICAL RESEARCH INSTITUTE OF SWEDEN   (Sweden)

^e ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 ({2 FLUORO 4 [(METHYLSULFONYL)METHYL]BENZYL}OXY) 2 {(2R) 2METHYL 4 [3 (TRIFLUOROMETHYL) 1,2,4 OXADIAZOL 5 YL]PIPERAZIN 1 YL} PYRIMIDINE; ALKYL GROUP; ANTICONVULSIVE AGENT; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; POTASSIUM CHANNEL HERG; SITAGLIPTIN; SULFONE; UNCLASSIFIED DRUG; 5-((2-FLUORO-4-((METHYLSULFONYL)METHYL)BENZYL)OXY)-2-(2-METHYL-4-(3-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOL-5-YL)PIPERAZIN-1-YL)PYRIMIDINE; ANTIDIABETIC AGENT; GPR119 PROTEIN, MOUSE; OXADIAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BRAIN SLICE; CLINICAL STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; TONIC CLONIC SEIZURE; VOLUME OF DISTRIBUTION; WILD TYPE; AGONISTS; ANIMAL; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DOG; DRUG EFFECTS; EPILEPSY, TONIC-CLONIC; KNOCKOUT MOUSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOGS; EPILEPSY, TONIC-CLONIC; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HYPOGLYCEMIC AGENTS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXADIAZOLES; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923767827     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5011012     Document Type: Article

References (57)

1. Fredriksson, R.; Höglund, P. J.; Gloriam, D. E. I.; Lagerström, M. C.; Schiöth, H. B. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives FEBS Lett. 2003, 554, 381-388
2. Overton, H. A.; Babbs, A. J.; Doel, S. M.; Fyfe, M. C. T.; Gardner, L. S.; Griffin, G.; Jackson, H. C.; Procter, M. J.; Rasamison, C. M.; Tang-Christensen, M.; Widdowson, P. S.; Williams, G. M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab. 2006, 3, 167-175
3. Chu, Z.; Carroll, C.; Chen, R.; Alfonso, J.; Gutierrez, V.; He, H.; Lucman, A.; Xing, C.; Sebring, K.; Zhou, J.; Wagner, B.; Unett, D.; Jones, R. M.; Behan, D. P.; Leonard, J. N -Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119 Mol. Endocrinol. 2010, 24, 161-170
4. Chu, Z.; Carroll, C.; Alfonso, J.; Gutierrez, V.; He, H.; Lucman, A.; Pedraza, M.; Mondala, H.; Gao, H.; Bagnol, D.; Chen, R.; Jones, R. M.; Behan, D. P.; Leonard, J. A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release Endocrinology 2008, 149, 2038-2047
5. Chu, Z.; Jones, R. M.; He, H.; Carroll, C.; Gutierrez, V.; Lucman, A.; Moloney, M.; Gao, H.; Mondala, H.; Bagnol, D.; Unett, D.; Liang, Y.; Demarest, K.; Semple, G.; Behan, D. P.; Leonard, J. A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release Endocrinology 2007, 148, 2601-2609
6. Fyfe, M. C. T.; McCormack, J. G.; Overton, H. A.; Procter, M. J.; Reynet, C. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity Expert Opin. Drug Discovery 2008, 3, 403-413
7. Shah, U. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders Curr. Opin. Drug Discovery Dev. 2009, 12, 519-532
8. Jones, R. M.; Leonard, J. N.; Buzard, D. J.; Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 1339-1359
9. Jones, R. M.; Leonard, J. N. The Emergence of GPR119 Agonists as Anti-Diabetic Agents. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: New York, 2009; Vol. 44, Chapter 7, pp 149-170.
10. Shah, U.; Kowalski, T. J. GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders. In Vitamins and Hormones; Litwack, G., Ed.; Academic Press: New York, 2010; Vol. 84, pp 415-448;.
11. Shah, U.; Edmondson, S.; Szewczyk, J. W. Recent Advances in the Discovery of GPR119 Agonists In New Therapeutic Strategies for Type 2 Diabetes; Jones, R. E., Ed.; RSC Publishing: Cambridge, UK, 2012; Vol. 27, pp 177-214.
12. Semple, G.; Fioravanti, B.; Pereira, G.; Calderon, I.; Uy, J.; Choi, K.; Xiong, Y.; Ren, A.; Morgan, M.; Dave, V.; Thomsen, W.; Unett, D. J.; Xing, C.; Bossie, S.; Carroll, C.; Chu, Z.; Grottick, A. J.; Hauser, E. K.; Leonard, J.; Jones, R. M. Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119 J. Med. Chem. 2008, 51, 5172-5175
13. Semple, G.; Ren, A.; Fioravanti, B.; Pereira, G.; Calderon, I.; Choi, K.; Xiong, Y.; Shin, Y.; Gharbaoui, T.; Sage, C. R.; Morgan, M.; Xing, C.; Chu, Z.; Leonard, J. N.; Grottick, A. J.; Al-Shamma, H.; Liang, Y.; Demarest, K. T.; Jones, R. M. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control Bioorg. Med. Chem. Lett. 2011, 21, 3134-3141
14. Semple, G.; Lehmann, J.; Wong, A.; Ren, A.; Bruce, M.; Shin, Y.; Sage, C. R.; Morgan, M.; Chen, W.; Sebring, K.; Chu, Z.; Leonard, J. N.; Al-Shamma, H.; Grottick, A. J.; Du, F.; Liang, Y.; Demarest, K.; Jones, R. M. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile Bioorg. Med. Chem. Lett. 2012, 22, 1750-1755
15. Zhang, J. (K.); Li, A.; Yu, M.; Wang, Y.; Zhu, J.; Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Eksterowicz, J.; Coward, P.; Liu, J. (J.) Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists Bioorg. Med. Chem. Lett. 2013, 23, 3609-3613
16. Yu, M.; Zhang, J. (K.); Wang, Y.; Zhu, J.; Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Coward, P.; Liu, J. (J.) Discovery and optimization of N -(3-(1,3-dioxo-2,3-dihydro-1 H -pyrrolo[3,4- c ]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 156-160
17. Wang, Y.; Yu, M.; Zhu, J.; Zhang, J. (K.); Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Liu, J. (J.); Coward, P. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 1133-1137
18. Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Oshima, H.; Yonetoku, Y.; Shibasaki, M. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice Biochem. Biophys. Res. Commun. 2010, 402, 280-285
19. Yoshida, S.; Tanaka, H.; Oshima, H.; Yamazaki, T.; Yonetoku, Y.; Ohishi, T.; Matsui, T.; Shibasaki, M. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes Biochem. Biophys. Res. Commun. 2010, 400, 745-751
20. Yoshida, S.; Ohishi, T.; Matsui, T.; Shibasaki, M. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion Biochem. Biophys. Res. Commun. 2010, 400, 437-441
21. Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Oshima, H.; Yonetoku, Y.; Shibasaki, M. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function Diabetes, Obes. Metab. 2011, 13, 34-41
22. Negoro, K.; Yonetoku, Y.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists Bioorg. Med. Chem. 2012, 20, 2369-2375
23. Negoro, K.; Yonetoku, Y.; Misawa-Mukai, H.; Hamaguchi, W.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists Bioorg. Med. Chem. 2012, 20, 5235-5246
24. Negoro, K.; Yonetoku, Y.; Moritomo, A.; Hayakawa, M.; Iikubo, K.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists Bioorg. Med. Chem. 2012, 20, 6442-6451
25. Oshima, H.; Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Yonetoku, Y.; Shibasaki, M.; Uchiyama, Y. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice Life Sci. 2013, 92, 167-173
26. Wellenzohn, B.; Lessel, U.; Beller, A.; Isambert, T.; Hoenke, C.; Nosse, B. Identification of New Potent GPR119 Agonists by Combining Virtual Screening and Combinatorial Chemistry J. Med. Chem. 2012, 55, 11031-11041
27. Wu, Y.; Kuntz, J. D.; Carpenter, A. J.; Fang, J.; Sauls, H. R.; Gomez, D. J.; Ammala, C.; Xu, Y.; Hart, S.; Tadepalli, S. 2,5-Disubstituted pyridines as potent GPR119 agonists Bioorg. Med. Chem. Lett. 2010, 20, 2577-2581
28. Katamreddy, S. R.; Carpenter, A. J.; Ammala, C. E.; Boros, E. E.; Brashear, R. L.; Briscoe, C. P.; Bullard, S. R.; Caldwell, R. D.; Conlee, C. R.; Croom, D. K.; Hart, S. M.; Heyer, D. O.; Johnson, P. R.; Kashatus, J. A.; Minick, D. J.; Peckham, G. E.; Ross, S. A.; Roller, S. G.; Samano, V. A.; Sauls, H. R.; Tadepalli, S. M.; Thompson, J. B.; Xu, Y.; Way, J. M. Discovery of 6,7-Dihydro-5 H -pyrrolo2,3- a ]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists J. Med. Chem. 2012, 55, 10972-10994
29. Gillespie, P.; Goodnow, R. A., Jr.; Saha, G.; Bose, G.; Moulik, K.; Zwingelstein, C.; Myers, M.; Conde-Knape, K.; Pietranico-Cole, S.; So, S. Discovery of pyrazolo[3,4- d ]pyrimidine derivatives as GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 949-953
30. Pham, T. N.; Yang, Z.; Fang, Y.; Luo, J.; Lee, J.; Park, H. Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists Bioorg. Med. Chem. 2013, 21, 1349-1356
31. McClure, K. F.; Darout, E.; Guimarães, C. R. W.; DeNinno, M. P.; Mascitti, V.; Munchhof, M. J.; Robinson, R. P.; Kohrt, J.; Harris, A. R.; Moore, D. E.; Li, B.; Samp, L.; Lefker, B. A.; Futatsugi, K.; Kung, D.; Bonin, P. D.; Cornelius, P.; Wang, R.; Salter, E.; Hornby, S.; Kalgutkar, A. S.; Chen, Y. Activation of the G-Protein-Coupled Receptor 119: A Conformation-Based Hypothesis for Understanding Agonist Response J. Med. Chem. 2011, 54, 1948-1952
32. Mascitti, V.; Stevens, B. D.; Choi, C.; McClure, K. F.; Guimarães, C. R. W.; Farley, K. A.; Munchhof, M. J.; Robinson, R. P.; Futatsugi, K.; Lavergne, S. Y.; Lefker, B. A.; Cornelius, P.; Bonin, P. D.; Kalgutkar, A. S.; Sharma, R.; Chen, Y. Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor Bioorg. Med. Chem. Lett. 2011, 21, 1306-1309
33. Kalgutkar, A. S.; Mascitti, V.; Sharma, R.; Walker, G. W.; Ryder, T.; McDonald, T. S.; Chen, Y.; Preville, C.; Basak, A.; McClure, K. F.; Kohrt, J. T.; Robinson, R. P.; Munchhof, M. J.; Cornelius, P. Intrinsic Electrophilicity of a 4-Substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine Derivative: Structural Characterization of Glutathione Conjugates in Vitro Chem. Res. Toxicol. 2011, 24, 269-278
34. Sharma, R.; Eng, H.; Walker, G. S.; Barreiro, G.; Stepan, A. F.; McClure, K. F.; Wolford, A.; Bonin, P. D.; Cornelius, P.; Kalgutkar, A. S. Oxidative Metabolism of a Quinoxaline Derivative by Xanthine Oxidase in Rodent Plasma Chem. Res. Toxicol. 2011, 24, 2207-2216
35. Darout, E.; Robinson, R. P.; McClure, K. F.; Corbett, M.; Li, B.; Shavnya, A.; Andrews, M. P.; Jones, C. S.; Li, Q.; Minich, M. L.; Mascitti, V.; Guimarães, C. R. W.; Munchhof, M. J.; Bahnck, K. B.; Cai, C.; Price, D. A.; Liras, S.; Bonin, P. D.; Cornelius, P.; Wang, R.; Bagdasarian, V.; Sobota, C. P.; Hornby, S.; Masterson, V. M.; Joseph, R. M.; Kalgutkar, A. S.; Chen, Y. Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119 J. Med. Chem. 2013, 56, 301-319
36. Futatsugi, K.; Mascitti, V.; Guimarães, C. R. W.; Morishita, N.; Cai, C.; DeNinno, M. P.; Gao, H.; Hamilton, M. D.; Hank, R.; Harris, A. R.; Kung, D. W.; Lavergne, S. Y.; Lefker, B. A.; Lopaze, M. G.; McClure, K. F.; Munchhof, M. J.; Preville, C.; Robinson, R. P.; Wright, S. W.; Bonin, P. D.; Cornelius, P.; Chen, Y.; Kalgutkar, A. S. From partial to full agonism: identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4- c ]pyrazole as a full agonist of the human GPR119 receptor Bioorg. Med. Chem. Lett. 2013, 23, 194-197
37. Xia, Y.; Chackalamannil, S.; Greenlee, W. J.; Jayne, C.; Neustadt, B.; Stamford, A.; Vaccaro, H.; Xu, X.; Baker, H.; ONeill, K.; Woods, M.; Hawes, B.; Kowalski, T. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes Bioorg. Med. Chem. Lett. 2011, 21, 3290-3296
38. Szewczyk, J. W.; Acton, J.; Adams, A. D.; Chicchi, G.; Freeman, S.; Howard, A. D.; Huang, Y.; Li, C.; Meinke, P. T.; Mosely, R.; Murphy, E.; Samuel, R.; Santini, C.; Yang, M.; Zhang, Y.; Zhao, K.; Wood, H. B. Design of potent and selective GPR119 agonists for type II diabetes Bioorg. Med. Chem. Lett. 2011, 21, 2665-2669
39. Sakairi, M.; Kogami, M.; Torii, M.; Kataoka, H.; Fujieda, H.; Makino, M.; Kataoka, D.; Okamoto, R.; Miyazawa, T.; Okabe, M.; Inoue, M.; Takahashi, N.; Harada, S.; Watanabe, N. Synthesis and SAR studies of bicyclic amine series GPR119 agonists Bioorg. Med. Chem. Lett. 2012, 22, 5123-5128
40. Sakairi, M.; Kogami, M.; Torii, M.; Makino, M.; Kataoka, D.; Okamoto, R.; Miyazawa, T.; Inoue, M.; Takahashi, N.; Harada, S.; Watanabe, N. Synthesis and Pharmacological Profile of a New Selective G Protein-Coupled Receptor 119 Agonist: 6-((2-Fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1 H -inden-1-one Chem. Pharm. Bull. 2012, 60, 1093-1095
41. Zhang, M.; Feng, Y.; Wang, J.; Zhao, J.; Li, T.; He, M.; Yang, D.; Nosjean, O.; Boutin, J.; Renard, P.; Wang, M. High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with Anti-Diabetic Efficacy in db / db Mice PLoS One 2013, 8, e63861
42. Sato, K.; Sugimoto, H.; Rikimaru, K.; Imoto, H.; Kamaura, M.; Negoro, N.; Tsujihata, Y.; Miyashita, H.; Odani, T.; Murata, T. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists Bioorg. Med. Chem. 2014, 22, 1649-1666
43. Katz, L. B.; Gambale, J. J.; Rothenberg, P. L.; Vanapalli, S. R.; Vaccaro, N.; Xi, L.; Polidori, D. C.; Vets, E.; Sarich, T. C.; Stein, P. P. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects Clin. Pharmacol. Ther. 2011, 90, 685-692
44. Katz, L. B.; Gambale, J. J.; Rothenberg, P. L.; Vanapalli, S. R.; Vaccaro, N.; Xi, L.; Sarich, T. C.; Stein, P. P. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes Diabetes, Obes. Metab. 2012, 14 (8) 709-716
45. Polli, J. W.; Hussey, E.; Bush, M.; Generaux, G.; Smith, G.; Collins, D.; McMullen, S.; Turner, N.; Nunez, D. J. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design Xenobiotica 2013, 43, 498-508
46. Brocklehurst, K. J.; Broo, A.; Butlin, R. J.; Brown, H. S.; Clarke, D. S.; Davidsson, Ö.; Goldberg, K.; Groombridge, S. D.; Kelly, E. E.; Leach, A.; McKerrecher, D.; ODonnell, C.; Poucher, S.; Schofield, P.; Scott, J. S.; Teague, J.; Westgate, L.; Wood, M. J. M. Discovery, optimization and in vivo evaluation of novel GPR119 agonists Bioorg. Med. Chem. Lett. 2011, 21, 7310-7316
47. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Broo, A.; Brown, H. S.; Butlin, R. J.; Clarke, D. S.; Davidsson, Ö.; Ertan, A.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Laber, D.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Pickup, A.; Schofield, P.; Svensson, P. H.; Sörme, P.; Teague, J. Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation J. Med. Chem. 2012, 55, 5361-5379
48. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Brown, H. S.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Poultney, R.; Schofield, P.; Svensson, P. H. Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists Med. Chem. Commun. 2013, 4, 95-100
49. Scott, J. S.; Brocklehurst, K. J.; Brown, H. S.; Clarke, D. S.; Coe, H.; Groombridge, S. D.; Laber, D.; MacFaul, P. A.; McKerrecher, D.; Schofield, P. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human Bioorg. Med. Chem. Lett. 2013, 23, 3175-3179
50. Easter, A.; Sharp, T. H.; Valentin, J.-P.; Pollard, C. E. Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability J. Pharmacol. Toxicol. Methods 2007, 56, 223-233
51. The intrinsic activity was expressed as the percent effect compared to that of the control, 50 μM oleoylethanolamide, defined as 100% as per Ariens, E. J. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory Arch. Int. Pharmacodyn. Ther. 1954, 99, 32-49
52. hERG measurements were made as described in: Bridgland-Taylor, M. H.; Hargreaves, A. C.; Easter, A.; Orme, A.; Henthorn, D. C.; Ding, M.; Davis, A. M.; Small, B. G.; Heapy, C. G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T. G.; Sullivan, E.; Valentin, J.-P.; Pollard, C. E. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT J. Pharmacol. Toxicol. Methods 2006, 54, 189-199
53. 7.4, plasma-protein binding and solubility measurements were made as described in: Buttar, D.; Colclough, N.; Gerhardt, S.; MacFaul, P. A.; Phillips, S. D.; Plowright, A.; Whittamore, P.; Tam, K.; Maskos, K.; Steinbacher, S.; Steuber, H. A. Combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions Bioorg. Med. Chem. 2010, 18, 7486-7496
54. Ertan, A.; Goldberg, K.; Groombridge, S.; Hudson, J.; Leach, A. G.; Pickup, A.; Poultney, R.; Scott, J. S.; Svensson, P. H.; Sweeney, J.; MacFaul, P. A. Oxadiazole isomers: all bioisosteres are not created equal Med. Chem. Commun. 2012, 3, 600-604
55. The media contained an aqueous mixture of TRIZMA (tris(hydroxymethyl)aminomethane) maleate, taurocholic acid, phosphatidyl choline, oleic acid, 1-oleoyl- rac -glycerol, sodium chloride at pH 6.4, and corresponds to media 2 in: Lue, B.-M.; Flemming, S. N.; Magnussen, T.; Schou, H. M.; Kristensen, K.; Jacobsen, L. O.; Müllertz, A. Eur. J. Pharm. Biopharm. 2008, 69, 648-657 The solubility figure quoted here was measured after one hour and did not change significantly over a 24 h period.
56. Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes, Obes. Metab. 2011, 13, 7-18
57. Marketed Small Molecule Dipeptidyl Peptidase IV (DPP4) Inhibitors as a New Class of Oral Anti-Diabetics In New Therapeutic Strategies for Type 2 Diabetes; Jones, R. E., Ed.; RSC Publishing: Cambridge, UK, 2012; Vol. 27, pp 15-28.